Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.


Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.


You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences’ rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences

Board of Directors


Michael Hunkapiller, Ph.D. | Chairman, CEO & President

Michael Hunkapiller became President & CEO of Pacific Biosciences in 2012. He is Chairman of PacBio’s Board of Directors, and has served on the Board since 2005. Dr. Hunkapiller spent over 30 years of his career helping build Applied Biosystems (“ABI,” now part of Thermo Fisher Scientific Inc.) into a market leader in the life sciences industry. From 1995 to 2004, he served as ABI’s President and General Manager. In 2004, he joined Alloy Ventures as a General Partner, and in 2005 led Alloy’s investment in PacBio. Dr. Hunkapiller continues to represent Alloy Ventures as a Director of NuGEN and RainDance Technologies.

During his term at ABI, Dr. Hunkapiller developed the R&D strategies and alliances that elevated ABI to be the foremost supplier of molecular-biology reagents and instrumentation in academic and industrial laboratories. He was also a founder of ABI’s sister company, Celera Genomics, and Senior Vice President of Applera Corporation (Celera’s parent company).

Prior to joining ABI, Dr. Hunkapiller was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech. He has authored more than 100 scientific publications, is an inventor on more than two-dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research.

MDV-Bill_EricsonBill Ericson | General Partner, Mohr Davidow Ventures (MDV) 

Bill Ericson joined MDV in 2000 after more than a decade of working closely with entrepreneurs to start and build innovative businesses in the role of lawyer, board member, entrepreneur, and investor. Mr. Ericson’s investment focus at MDV is primarily in life sciences, with a current specific focus on molecular diagnostics and platforms that will enable the vision of personalized medicine. He works closely with a cross-disciplinary team of leading scientists, researchers, and entrepreneurs, and seeks to apply technology solutions to life sciences in non-traditional ways.

Prior to MDV, Mr. Ericson founded and ran Venture Law Group’s Seattle office. He is particularly proud of being a member of the founding team of Rosetta Inpharmatics and serving on its Board of Directors until its acquisition by Merck in 2001.

In addition to serving on the board of Pacific Biosciences, Mr. Ericson is also on the board of Adamas Pharmaceuticals, Artemis Health, Cellpoint Diagnostics, nLight Photonics, RainDance Technologies, Revenue Science, Sabrix, Tethys Bioscience, and Visible Measures.

He serves on the Board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition. Mr. Ericson received his B.S.F.S. from Georgetown University of Foreign Service and his J.D. from Northwestern University School of Law.

David Botstein PhotoDavid Botstein, Ph.D. | Chief Scientific Officer, Calico Life Sciences, LLC

David Botstein is Chief Scientific Officer of Calico Life Sciences, LLC. He is also Anthony B. Evnin Professor of Genomics, Emeritus at Princeton University, where he served as Director of the Lewis-Sigler Institute for Integrative Genomics. From 1990–2003, Dr. Botstein was Chairman of the Department of Genetics at Stanford University. From 1987–1990, he was Vice President for Science at Genentech and remained a member of its Science Resource Board until 2014. He is a member of the National Academy of Sciences and the Institute of Medicine, and has received numerous awards for his achievements in science.

Dr. Botstein has made fundamental contributions to modern genetics, including the discovery of many yeast and bacterial genes and the establishment of key techniques that are commonly used today. In 1980, Dr. Botstein and three colleagues proposed a method for mapping genes that laid the groundwork for the Human Genome Project. He holds a Ph.D. in Human Genetics from the University of Michigan and an A.B. in Biochemical Sciences from Harvard.

BByersHighResBrook Byers | Partner, Kleiner Perkins Caufield & Byers (KPCB)

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. Mr. Byers formed the first life sciences practice group in the venture capital profession in 1984, and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors.

Mr. Byers was President and a Director of the Western Association of Venture Capitalists, and is currently on the Board of Trustees of Stanford University. He also serves on the Board of Overseers of the University of California, San Francisco medical campus and hospitals, and the Board of Directors of the New Schools Foundation. In addition, Mr. Byers currently sits on the Board of Directors for CareDX, Enjoy Technology, Octave Bioscience, Oculeve, and Zephyr Health. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Phamacopeia, Hybritech (Chairman), Genprobe, and others.

In 2007, UCSF awarded Mr. Byers the UCSF Medal, its honorary degree equivalent. In 2008, he was elected a fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. In 2010, he received an honorary Ph.D. from Georgia Institute of Technology. He earned a B.S. in electrical engineering from Georgia Tech and his M.B.A. from Stanford University.

Randy Livingston | Vice President for Business Affairs and Chief Financial Officer, Stanford University

Randy Livingston has been Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001. Before joining Stanford, Mr. Livingston spent 16 years as a finance, marketing, and corporate development executive for several Silicon Valley companies, and six years as a consultant at McKinsey & Company. Mr. Livingston currently serves as a director of Genomic Health, eHealth, Inc., and the Stanford Management Company. He holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

MarsMarshall Mohrhall L. Mohr | Senior Vice President & Chief Financial Officer, Intuitive Surgical

Marshall L. Mohr joined Intuitive Surgical in March 2006. Prior to that, Mr. Mohr was Vice President and Chief Financial Officer of Adaptec, Inc. Before joining Adaptec in July 2003, Mr. Mohr was an Audit Partner with PwC, where he was most recently the Managing Partner of the firm’s west region technology industry group. He also led its Silicon Valley accounting and audit advisory practice. Mr. Mohr serves on the board of directors for Plantronics, Inc. He received his B.B.A. in Accounting and Finance from Western Michigan University.

John Milligan - new high resJohn F. Milligan, Ph.D. | President and Chief Operating Officer, Gilead Sciences

John Milligan joined Gilead Sciences in 1990 as a research scientist, and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.

Named “Bay Area CFO of the Year” in 2006 for companies with revenues greater than $500 million, Dr. Milligan was also named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007, and 2008. In 2008, Dr. Milligan joined the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization. He is a Trustee of Ohio Wesleyan University.

Dr. Milligan received his B.A. from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois, and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

Kathy Ordoñez | Director of Pacific Biosciences, Inc.

Kathy Ordoñez brings more than 30 years of experience in the life sciences and diagnostics industries. Previously, Ms. Ordoñez was a Senior Vice President at Quest Diagnostics, where she was initially responsible for leading the company’s R&D efforts and later provided oversight to multiple businesses commercializing diagnostic products and testing services. She joined Quest Diagnostics as part of its acquisition of Celera Corporation in 2011.

Ms. Ordoñez was previously the Chief Executive Officer at Celera and a founder of Celera Diagnostics. Under her leadership, Celera became the leading provider of genetic-testing products for HIV resistance, cystic fibrosis, and high-complexity tissue transplantation. Earlier in her career, Ms. Ordoñez held several senior positions at Hoffmann-La Roche. There, she oversaw the formation of Roche Molecular Systems, where she served as President and Chief Executive Officer and led the wide-scale commercial application of the Polymerase Chain Reaction (PCR) technology to the research, diagnostic, and forensic fields.

Lucy_Shapiro_headshotLucy Shapiro | Developmental Biology Professor, Stanford University School of Medicine

Lucy Shapiro currently serves as the Virginia and D.K. Ludwig Professor of Cancer Research and the Director of the Beckman Center for Molecular and Genetic Medicine at Stanford University’s School of Medicine, where she has been a faculty member since 1989. Dr. Shapiro is a co-founder and director of Anacor Pharmaceuticals, Inc. In 1989, she founded Stanford University’s Department of Developmental Biology and served as its Chairman until 1997. Prior to that, Dr. Shapiro served as Chair of the Department of Microbiology and Immunology in the College of Physicians and Surgeons of Columbia University.

Dr. Shapiro has received numerous awards and has been elected to the National Academy of Sciences, the American Academy of Microbiology, the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences for her work in the fields of molecular biology and microbiology. Dr. Shapiro previously served as a non-executive director of GlaxoSmithKline plc from 2001 to 2006.

She received a B.A. from Brooklyn College and a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine.